Relacorilant Provides Significant Benefit Across Cardiometabolic Outcomes in Global Statistical Tests of the Placebo-controlled, Randomized-withdrawal GRACE Trial in Cushing Syndrome

Hand et al. • 2026 • CMHC

Read more

Characteristics Associated With Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disorders: Analyses From the MOMENTUM Study

Al Dhaybi et al. • 2026 • AHA HTN

Read more

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

DeFronzo et al. • 2026 • Heart in Diabetes

Read more

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

DeFronzo et al. • 2026 • ENDO

Read more

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

Eilerman et al. • 2026 • ENDO

Read more

Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

Silverstein et al. • 2026 • AACE

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube